The role of TRPV1 receptor in the hypothalamus

2011 ◽  
Author(s):  
A. Zsombok ◽  
H. Gao ◽  
K. Myata ◽  
K D. Hebert ◽  
M. D. Bhaskaran ◽  
...  
Keyword(s):  
2015 ◽  
Vol 148 (4) ◽  
pp. S-887
Author(s):  
Chien-Lin Chen ◽  
Tso-Tsai Liu ◽  
Chih-Hsun Yi ◽  
Wei-Yi Lei ◽  
Jui-Sheng Hung

2018 ◽  
Vol 30 (8) ◽  
pp. e13340 ◽  
Author(s):  
R. O. Silva ◽  
R. D. Bingana ◽  
T. M. A. L. Sales ◽  
R. L. R. Moreira ◽  
D. V. S. Costa ◽  
...  

2005 ◽  
Vol 169 (1-2) ◽  
pp. 86-96 ◽  
Author(s):  
Ágnes Bánvölgyi ◽  
László Pálinkás ◽  
Tímea Berki ◽  
Natalie Clark ◽  
Andrew D. Grant ◽  
...  

Life Sciences ◽  
2007 ◽  
Vol 81 (13) ◽  
pp. 1094-1102 ◽  
Author(s):  
Christophe Faisy ◽  
Benjamin Planquette ◽  
Emmanuel Naline ◽  
Paul-André Risse ◽  
Nelly Frossard ◽  
...  

2017 ◽  
pp. 549-552 ◽  
Author(s):  
N. KALYNOVSKA ◽  
P. ADAMEK ◽  
J. PALECEK

Transient receptor potential vanilloid type 1 (TRPV1) receptors are important in the development of different pathological chronic pain states. Here we examined the role of spinal cord TRPV1 receptors in the mechanisms leading to activation of dorsal horn neurons after paclitaxel (PAC) treatment. PAC is a widely used chemotherapeutic drug that often leads to development of painful neuropathy. Immunohistochemical analysis of c-Fos protein expression in dorsal horn neurons was used as a marker of neuronal activation. Rat spinal cord slices were processed for in vitro incubation with PAC (100 nM) and TRPV1 receptor antagonists (SB366791 and AMG9810; 10 µM). PAC treatment induced significant upregulation of c-Fos nuclear expression in superficial dorsal horn neurons that was diminished by TRPV1 receptor antagonists pre-incubation. These results further substantiated the role of spinal TRPV1 receptors in the development of paclitaxel-induced neuropathic pain and contribute to better understanding of the pathological mechanisms involved.


2021 ◽  
Vol 4 ◽  
Author(s):  
Hector Emmanuel Cortés-Ferré ◽  
Daniel Guajardo-Flores ◽  
Gregorio Romero-De La Vega ◽  
Janet Alejandra Gutierrez-Uribe

The hot chili pepper industry represents one of the most important staple foods in Mexico and many Asian countries. Nowadays, large amounts of waste materials are produced from the pepper supply chain that could be used as a source to obtain nutraceuticals. Among the most common and important bioactive compounds contained in pepper residues are the capsaicinoids, which are the responsible of the pungency of the pepper. Capsaicinoids, mainly capsaicin, may ameliorate obesity, gastric disorder, diabetes, cardiovascular diseases, cancer, rhinitis, asthma, immune system diseases, and important viral diseases as the recent COVID-19. The aim of this review is to review the industrial process for the extraction of capsaicinoids ingredients from pepper residues and to examine the relation of the capsaicin and other chili pepper phytochemicals to prevent and treat chronic diseases explained through the key role of the TRPV1 receptor. The extraction and incorporation of these compounds into nutraceutical formulations depend mainly on the development of new methods to improve not only the yield of a particular compound but the validation of the bioactivity and phytochemical characterization.


Sign in / Sign up

Export Citation Format

Share Document